Unknown

Dataset Information

0

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.


ABSTRACT: We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer.This trial was a randomized, two-armed, non-inferiority phase 3 comparison of CapeOX (capecitabine 1000 mg/m2 twice daily on days 1-14 and oxaliplatin 130 mg/m2 on day 1) versus SOX (S-1 40 mg/m2 twice daily on days 1-14 and oxaliplatin 130 mg/m2 on day 1). The primary end point was to show non-inferiority of SOX relative to CapeOX in terms of PFS. Thus, a follow-up exploratory analysis of PFS and OS was performed.The intention to treat (ITT) population was comprised of 340 patients (SOX arm: 168 and CapeOX arm: 172). The updated median PFS was 7.1 months (95% CI 6.4-8.0) in the SOX group and 6.3 months (95% CI 4.9-6.7) in the CapeOX group (hazard ratio [HR], 0.83 [0.66-1.04], p =?.10). The median OS was 19.0 months (95% CI 15.3-23.0) in the SOX group and 18.4 months (95% CI 14.1-20.7) in the CapeOX group (HR, 0.86 [0.68-1.08], p =?.19). Subgroup analyses according to principal demographic factors such as sex, age, ECOG (Eastern Cooperative Oncology Group) performance status, primary tumor location, measurability, previous adjuvant therapy, number of metastatic organs, and liver metastases showed no interaction between any of these characteristics and the treatment.Updated survival analysis shows that SOX is similar to CapeOX, confirming the initial PFS analysis. Therefore, the SOX regimen could be an alternative first-line doublet chemotherapy strategy for patients with metastatic colorectal cancer.NCT00677443 and May 12 2008.

SUBMITTER: Kim ST 

PROVIDER: S-EPMC4289339 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.

Kim Seung Tae ST   Hong Yong Sang YS   Lim Ho Yeong HY   Lee Jeeyun J   Kim Tae Won TW   Kim Kyu-Pyo KP   Kim Sun Young SY   Baek Ji Yeon JY   Kim Jee Hyun JH   Lee Keun-Wook KW   Chung Ik-Joo IJ   Cho Sang-Hee SH   Lee Kyung Hee KH   Shin Sang Joon SJ   Kang Hye Jin HJ   Shin Dong Bok DB   Lee Jae Won JW   Jo Sook Jung SJ   Park Young Suk YS  

BMC cancer 20141126


<h4>Background</h4>We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer.<h4>Methods</h4>This trial was a randomized, two-armed, non-inferiority phase 3 comparison of CapeOX (capecitabine 1000 mg/m2 twice daily on days 1-14 and oxaliplatin 130 mg/m2 on day 1) versus SOX (S-1 40 mg/m2 twice daily on days 1-14 an  ...[more]

Similar Datasets

| S-EPMC9354395 | biostudies-literature
| S-EPMC3399650 | biostudies-literature
| S-EPMC3173448 | biostudies-literature
| S-EPMC3174848 | biostudies-literature
| S-EPMC2844042 | biostudies-literature
| S-EPMC5181797 | biostudies-other
| S-EPMC4893985 | biostudies-literature
| S-EPMC4618621 | biostudies-literature
| S-EPMC3311029 | biostudies-literature
| S-EPMC4478977 | biostudies-literature